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Vy-PER: eliminating false positive 
detection of virus integration 
events in next generation 
sequencing data
Michael Forster1,*, Silke Szymczak1,*,†, David Ellinghaus1, Georg Hemmrich1, 
Malte Rühlemann1, Lars Kraemer1, Sören Mucha1, Lars Wienbrandt2 & Martin Stanulla3, 
UFO Sequencing Consortium within the I-BFM Study Group4, Andre Franke1
Several pathogenic viruses such as hepatitis B and human immunodeficiency viruses may integrate 
into the host genome. These virus/host integrations are detectable using paired-end next generation 
sequencing. However, the low number of expected true virus integrations may be difficult to 
distinguish from the noise of many false positive candidates. Here, we propose a novel filtering 
approach that increases specificity without compromising sensitivity for virus/host chimera detection. 
Our detection pipeline termed Vy-PER (Virus integration detection bY Paired End Reads) outperforms 
existing similar tools in speed and accuracy. We analysed whole genome data from childhood acute 
lymphoblastic leukemia (ALL), which is characterised by genomic rearrangements and usually 
associated with radiation exposure. This analysis was motivated by the recently reported virus 
integrations at genomic rearrangement sites and association with chromosomal instability in liver 
cancer. However, as expected, our analysis of 20 tumour and matched germline genomes from ALL 
patients finds no significant evidence for integrations by known viruses. Nevertheless, our method 
eliminates 12,800 false positives per genome (80× coverage) and only our method detects singleton 
human-phiX174-chimeras caused by optical errors of the Illumina HiSeq platform. This high accuracy 
is useful for detecting low virus integration levels as well as non-integrated viruses.
Two primary drivers for developing virus integration detection methods are the fields of disease ther-
apy and disease etiology. In gene therapy and immunotherapy studies, a major consideration is the 
non-integration1 or at least the safe integration of a vector’s payload into the host genome2–4. In dis-
ease etiology, prominent examples of integrations into the host genome are the retroviruses human 
T-lymphotropic virus (HTLV) in adult T-cell leukemia5 and human immunodeficiency virus (HIV) in 
acquired immune deficiency syndrome (AIDS). Recent studies reported that integration of HIV at spe-
cific genomic locations leads to clonal expansion of virus-infected cells – slowing viral decay under 
combination antiretroviral therapy (cART) – and to cancer initiation6,7. Other etiologically important 
viruses that may integrate using different methods are hepatitis B virus (HBV) in liver cancer and human 
papillomavirus (HPV) in cervical, anal, oropharynx and other cancers8–10. Epstein-Barr virus (EBV) is 
associated with Burkitt’s lymphoma11 and is routinely used to immortalise cell lines12,13, but has also been 
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reported to integrate into the host genome at very low frequencies14–16. Regardless of whether viruses 
are integrated into the host genome or not, one causal mechanism for cancer development is binding of 
virus proteins to the tumour suppressor p53, thereby inhibiting apoptosis. This mechanism is exploited 
for example by HBV17, HPV18, herpes simplex type 119, measles20, or simian virus type 4021. Another 
causal mechanism was hypothesised when HBV integration throughout the human genome was detected 
in liver cancer22 and associated with genomic instability, putatively caused by fusion transcripts. A third 
causal mechanism was more recently suggested when HBV integration sites were found to recurrently 
cluster near genomic rearrangement sites and were therefore associated with chromosomal instability 
(chromothripsis)23–25. This discovery led to systematic and large-scale virus integration analyses of The 
Cancer Genome Atlas data11,26, and of data in many ongoing cancer studies including the childhood 
acute lymphoblastic leukemia (ALL) deep sequencing pilot study initiated by the German Federal Office 
for Radiation Protection (http://goo.gl/q7SaUZ). Childhood ALL is mostly classifiable by fusion genes27,28 
and is usually associated with exposure to radiation29,30, like other childhood cancers31. The exact causes 
of ALL remain unknown. To our knowledge, there have been no previous studies on virus integrations 
in childhood ALL.
Virus integrations can be detected using Illumina paired-end sequencing (Fig. 1), if one read maps 
to the human genome and its paired end to a virus genome23,24. We analysed our childhood leukemia 
data accordingly using own scripts, as the data were too large for publicly available pipelines even on our 
high performance Linux cluster (928 cores with the hardware limit of 125 GB RAM per job). In addition, 
the pipelines that we tested were quite slow and did not detect virus integrations in benchmarking runs 
of our leukemia data. Our initial scripts identified a surprisingly large number of virus candidates. On 
closer inspection we noticed that many virus candidates were simply long stretches of unspecific short 
tandem repeats (STRs) or homopolymers (Table  1). These unspecific sequence stretches turned out to 
be identical in many virus genomes as well as the human genome. We therefore developed filters to 
eliminate false positives efficiently without compromising the sensitivity to detect true chimeric human/
virus sequences. One solution to eliminate nearly all false positives would be to filter low-complexity 
reads with DUST32, as implemented for example in BLAST33 searches, or with PRINSEQ34. To avoid 
Classical Variant-Calling pipeline 
(BWA / GATK / SAMtools) 
Virus Integration Detection module 
for Classical Variant-Calling pipeline 
human reference hg19 
known virus references 
human paired-end reads 
NGS paired-end reads from human 
sample 
stringent alignment to human 
genome (hg) 
local re-alignment around indels 
unmapped reads of partially 
mapped pairs 
discard low-complexity reads 
alignment to virus genomes 
final virus integration candidates 
SNV calling 
 
indel calling 
 
SV calling 
final SNV, indel, and SV 
candidates 
discard low-complexity candidates 
discard candidates with exact 
alignment to hg (Smith-Waterman) 
Figure 1. Detection of virus integrations into the human genome using paired-end sequencing. After 
the computationally expensive classical alignment of all paired-end reads to the human genome, the pipeline 
splits into classical variant calling and virus integration detection.
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removing potentially informative reads (see Supplementary Results online), we prefer to filter reads by 
only considering the length of its longest STR. A second solution to eliminate false positives would be to 
cluster the virus/human chimera candidates within a genomic window as implemented in the VirusSeq 
pipeline26, but this method by definition loses the sensitivity to detect low-frequency events represented 
by singleton or low-frequency chimeras. A third method would be to obtain supporting information on 
potential viruses from unmapped read-pairs, as implemented in the VirusSeq and VirusFinder pipe-
lines35, which is limited to the co-occurrence of a virus, not its integration into the host genome. Our 
aim for high sensitivity was motivated by the knowledge that for example HIV or HTLV has a tropism 
for T-lymphocytes with CD4 receptors36,37, leaving most other cell types uninfected, and that viruses such 
as EBV or HTLV integrate at seemingly random sites and are difficult to detect unless a major clonal 
expansion takes place within the cell population14–16,37. With respect to the efficient use of computer 
resources, the computationally expensive alignment of all read-pairs to the human genome should ideally 
be performed just once, i.e. in the context of a classical BWA-based next generation sequencing (NGS) 
pipeline (Fig.  1). The resulting specific and efficient analysis pipeline would allow us to routinely scan 
all of our future genome, transcriptome, and targeted next generation sequencing data for integrations 
of known viruses before further wet lab tests or computationally more expensive analyses are performed 
on selected samples.
Material and Methods
Whole genome sequencing of leukemia samples. In 2012 the German Federal Office for Radiation 
Protection initiated a multi-center deep sequencing pilot study on childhood ALL (Supplementary con-
sortium data online). We sequenced the whole genomes of paired tumour and control samples from ten 
pediatric patients according to the Illumina TruSeq paired-end sequencing protocol. The tumours had 
characteristic genomic rearrangements detected by PCR38. Samples were taken at diagnosis in different 
hospitals. The tumour cell content was between 60% and 95%. Each tumour sample was sequenced to a 
minimal coverage of 80× using an average of eight HiSeq 2000 lanes. As in nearly all current leukemia 
studies, the control samples were collected from the same patients when they were in remission, defined 
by a tumour cell content (MRD, minimal residual disease) less than 0.01%. Each control sample was 
sequenced to a minimal coverage of 40× using an average of four lanes.
The paired tumour and control samples were collected within the International BFM-Study Group 
(I-BFM-SG) from Austria, France, and Germany. The patients were enrolled by the AIEOP-BFM 
study group (Austria, Germany) and the FRALLE study group (France). Informed consent for the 
use of spare specimens for research was obtained from study individuals, parents or legal guardians. 
The research project reported here was approved by the Ethics Committee of the Medical Faculty, 
Christian-Albrechts-University, Kiel, Germany. All methods were carried out in accordance with the 
approved guidelines. The biological samples and sequence data are not consented for access outside of 
our consortium.
Whole genome sequencing protocol. Illumina TruSeq 2 × 101 bp paired end sequencing was per-
formed on Illumina HiSeq 2000 and HiSeq 2500 instruments (Illumina, San Diego, CA). In brief, we 
used 1 μ g of DNA per sample, which is fragmented by sonication to lengths of approximately between 
250 and 650 bps before end-repair and ligation of Illumina sequencing adapters and molecular barcodes. 
The resulting libraries are each attached to random positions on a glass carrier plate (flowcell), and 
sequenced: Put simply, in the “first run”, the positions of all clusters on the glass plate are optically iden-
tified, and the first end of each library is sequenced to a length of 101 bps. In the second run, the library 
is sequenced from the second end to a length of 101 bps. Importantly, the position of each library on the 
flowcell is optically identified by the instrument and in rare cases a library position may be identified dif-
ferently in the second run, leading to a chimeric sequencing artefact consisting of two different libraries.
Bioinformatic availability and implementation. All Vy-PER scripts (Virus integration detection 
bY Paired End Reads) are freely available at http://www.ikmb.uni-kiel.de/vy-per. The downloads include 
example scripts for a Linux cluster, human genome hg19 reference, NCBI virus genome references 
Virus candidate sequence Probable virus candidate More likely explanation
TTAGGGTTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCT Cyprinid herpesvirus 3 STR (human telomere)
CTCTCTCTCTCTCTCTCACACACACACACACACACACACACACACACACACACAC Ictalurid herpesvirus 1 STRs
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTA Caviid herpesvirus 2 mainly homopolymer
TATATATATATATATATATATATATATTTTTTTTTTTTTTTTTTTTTTTT Cotesia congregata bracovirus STR and homopolymer
AACCCTAACCCTAACCCTAACCCTAACCCTAACCCTANCCCTAACCCTA Human herpesvirus 6A STR (human telomere)
TAACCCTAACCCTAACCCTAACCCTAGCCCTAACCCTAACCCTAACCCTA Human herpesvirus 7 STR (human telomere)
Table 1.  Typical false positive virus candidates before final filtering.
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and benchmark data. The Vy-PER scripts are implemented in Python 2.7 with pysam v0.6, R, the 
Bioconductor39 packages quantsmooth40 and RColorBrewer, and bash scripts. Further prerequisites are 
BLAT41, BWA42, Phobos 3.3.12 (Christoph Mayer, http://www.rub.de/spezzoo/cm/cm_phobos.htm), and 
SAMtools43. For final filtering we used a Smith-Waterman implementation on the FPGA-based hardware 
RIVYERA S6-LX150 from SciEngines (www.sciengines.com), but for general users, Vy-PER also pro-
vides the option of using BLAT on a Linux cluster.
The bioinformatic workflow is summarised in Fig.  1 and described in detail in the Supplementary 
Methods online. In brief, the first step is the classical alignment of the human sequencing reads to 
the human genome prior to classical NGS variant calling, for example using BWA and SAMtools. This 
alignment is generally performed with stringent settings to keep run-time low and to map reads with 
high confidence for subsequent variant calling. However, a percentage of human reads will remain as 
“unmapped reads” that could not be aligned to the human reference. After this first step, the pipeline 
splits into two sub-pipelines that can be run in parallel if a computer cluster is available: (i) classical 
variant-calling, and (ii) virus integration detection. In the virus detection sub-pipeline, the first step is 
to extract paired-ends for which one read aligned to the human genome and the other end did not. The 
second step is to discard low-complexity reads with a long short tandem repeat or homopolymer. The 
third step is to test remaining reads for viral origin by alignment to known virus genomes. Some reads 
may map full-length or partially to a virus genome. In the fourth step, these candidate virus sequences 
are tested for low complexity, as a partial-length mapping result to a virus genome may consist only of a 
short tandem repeat or homopolymer (Table 1). In the final step, the remaining candidate sequences are 
tested for human origin using exact alignment to the human genome. This is computationally extremely 
expensive and can therefore usually be performed for only a few hundred sequences on a normal Linux 
computer cluster, hence the preceding multi-step filtering/testing process. Two sub-steps are used to 
speed up this exact alignment to the human genome: Each candidate is exactly aligned to its own small 
reference sequence window around the end of the read-pair that mapped to the human genome. Those 
candidates failing the first, local alignments are consecutively exactly aligned against the entire human 
genome. For exact alignment, BLAT is used with special settings (Supplementary Methods online), and 
for optional speed increase we use the Smith-Waterman implementation on FPGA hardware.
Bioinformatic pipeline comparison. We here also compare the virus integration detection by 
Vy-PER with several recently published pipelines using their default settings or recommendations: the 
VirusSeq pipeline26, the VirusFinder pipeline v.2.035, and the ViralFusionSeq pipeline revision128944. As 
the VirusFinder pipeline does not include virus reference sequences on its project homepage, we fol-
lowed the authors’ recommendations and downloaded the RINS reference sequences45. Out of interest, 
we also used VirusSeq’s gibVirus reference sequences (http://gib-v.genes.nig.ac.jp/) for VirusFinder. The 
benchmark timings were obtained by running each pipeline on a single 16-core linux computer node 
with 120 GB RAM, except for Vy-PER which only required a single core and less than 10 GB RAM; all 
file input/output was performed via a 10 Gbit/s network to a central EMC Isilon X200 storage cluster. We 
included the Amazon EC2 cloud-based instance of SURPI46 for detecting the presence of viruses without 
the ability to detect their integration. We tested SURPI v1.0.18 (July 10, 2014) using the EC2 Amazon 
Machine Image ami-a28f4cca on an i2.4xlarge instance in Amazon’s US-East region, as described in the 
SURPI protocol.
Example data for the bioinformatic pipeline comparison. Download links to all four example 
data sets are available at http://www.ikmb.uni-kiel.de/vy-per.
NA12878V is a synthetic data set that we constructed by extracting 10,000 read-pairs from a 1000 
Genomes Project47 Illumina paired-end whole genome sequencing BAM file for individual NA1287848 
and adding 11,205 read-pairs from multiple individuals. The 11,205 read-pairs consist of 9,832 human/
human pairs and 1,373 human/virus chimeras: The human/virus chimeras comprise 1,334 enterobac-
teria phage phiX174 chimeras, 2 enterobacteria phage M13 chimeras, and 37 human herpes virus type 
3 (HHV-3) chimeras. The 9,832 human/human read-pairs include sequence stretches with similarities 
to virus sequence stretches, in order to test whether the benchmarked pipelines incorrectly detect her-
pes viruses (false positives). For patient confidentiality reasons, the original FASTQ sequence files and 
sequences in analysis or results files are removed from the publicly downloadable data. The paired-ends 
were aligned to hg19 using BWA and SAMtools. Then the Vy-PER pipeline was run as described.
L526401A liver cancer sample (RNA). As our patient data cannot be publicly released, we here demon-
strate the detection of known HBV integrations into liver cancer cell genomes employing publicly availa-
ble Illumina paired-end (2 × 50 bp) transcriptome data26 with known HBV integrations. Before Vy-PER 
was run, the 53,060,622 paired-ends were aligned to hg19 using BWA and SAMtools, which required 3 h 
2 minutes on a 16-core node. Then the Vy-PER pipeline was run as described.
198T and 268T comprise publicly available “cleaned” Illumina paired-end (2 × 90 bp) whole genome 
tumour data with known HBV integrations, from two liver cancer patients in a study of 88 liver cancer 
patients23. The original raw sequences do not seem to be publicly available. We selected subsets of 198T 
and 268T sequencing data to test the sensitivity of our method and of other approaches at ultra low 
virus integration content. The subsets consist of 82,708,061 (198T) and 82,450,511 (268T) read-pairs, 
respectively. Before the Vy-PER run, alignment to hg19 was performed using BWA and SAMtools, which 
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required 3 hours 22 minutes (198T), and 3 hours 45 minutes (268T), respectively. Then the Vy-PER pipe-
line was run as described.
Results
No evidence of somatic virus integration in childhood acute lymphoblastic leukemia samples 
with genomic rearrangements. Using our Vy-PER method, we searched for virus integrations in 10 
tumour samples that were sequenced to a minimal coverage of 80× , and in 10 matched normal samples 
from the same patients that were sequenced to a minimal coverage of 40× . Before final filtering (see 
Supplementary Methods online), we detected on average 1600 virus candidates per lane (12,800 per 
80× genome). On manual inspection, most candidates appeared to be false positives. Table  1 shows a 
representative snapshot of false positive virus candidates with intriguingly plausible viruses, e.g. the com-
mon herpes viruses. However, their candidate sequences are non-specific STR-rich or homopolymer-rich 
sequences. It can be argued that some herpes types are known to integrate into human telomeres49, 
but on the other hand, some herpes virus genomes simply have homologies to the human telomeres50. 
When we aligned a number of full-length HiSeq reads from herpes candidates to the expected human 
genome sequence window using an interactive DIALIGN-based tool51, we found that these reads were 
in fact from the human genome. Our alignment exercise suggested that a more accurate and more sen-
sitive alignment of the virus candidates to the host genome would be an effective filter to eliminate false 
positives. Therefore, we implemented the final filtering of candidates (Fig. 1). The STR-based filtering of 
virus candidate sequences and exact alignment of remaining sequences to the expected human genome 
window cut the number of false positive virus candidates to only 12 candidates per 80× genome, on 
average. The final exact alignment to the whole human genome eliminated most of these remaining few 
sequences. In the end, no true virus/human chimeras were detected (Fig. 2, Table 2) even at the lowest 
reporting threshold of 1 paired-end in 20 M bps. The only reported candidates were sparsely distributed 
phiX174 chimeras, a few singletons, and a cluster of three enterobacteria phage M13 chimeras in the 
remission sample of patient 8 but not in the tumour. The phiX chimeras are probably optical positioning 
errors of the HiSeq platform when the sequencing of the second read of a paired-end run is performed. 
PhiX libraries are technical controls for base calling on the Illumina platforms. They are spiked into the 
completed sample libraries as a fraction of about 1% of the total libraries. The phiX libraries should not 
normally ligate with sample libraries, as both libraries are blunt-ended. The fraction of phiX chimeras 
in the ALL samples comprised about 0.0001% of the total paired-ends, or about 160 chimeras per lane. 
Enterobacteria phage M13 is used for bacterial cloning, as in the commercial production of phiX. The 
M13 singletons and the small M13 cluster that we detected are a trace contaminant of the Illumina 
phiX174 libraries. This suggests that our STR-filtering and host-genome re-alignment strategy is very 
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Figure 2. Vy-PER ideogram summary plot. Negative example without true virus integrations: Patient 
genome sequenced with 40× coverage and analysed with highest sensitivity, eliminating 6400 false positives 
and leaving three unsupported singletons (pseudomonas phage, caviid herpes, cercopithecine herpes) which 
we manually eliminated as alignment artefacts. PhiX and M13 originated from the 1% Illumina sequencing 
library control spike-in. The plot shows integration sites down to single chimeras.
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promising for the elimination of human sequence reads and the preservation of virus/host chimeras, 
even down to singletons.
Bioinformatic pipeline comparison. Childhood acute lymphoblastic leukemia whole genome data 
from one HiSeq lane. To compare run times between different pipelines (Table 3), we selected one HiSeq 
2000 lane of data from one childhood ALL sample and ran each pipeline on an identical 16-core com-
puter, except for Vy-PER which only requires a single core. One lane is approximately equivalent to a 10× 
covered genome. Analysis of the full genomic data was not feasible due to the computational duration 
and the unavailability of sufficient computing resources. After the classical BWA/SAMtools alignment to 
hg19, which required 13.5 hours, Vy-PER completed within 1 hour. VirusFinder required only 12.75 hours 
because it did not detect any viruses, but each detected virus would roughly add another 13 hours due 
to the renewed alignment of all reads to a combined hg19/virus reference sequence. ViralFusionSeq 
required 19 hours, the greater part of which is due to BWA-SW alignment which can be slower than 
BWA alignment. VirusSeq ran for 195 hours, mainly due to its use of the Mosaik aligner52, and failed in 
its final step. We could not test the Amazon EC2 cloud based instance of SURPI on this data set, due 
to severe performance issues. With respect to their detection results, VirusFinder, ViralFusionSeq and 
VirusSeq did not report human/virus chimeras in the leukemia data set (Table  4), ignoring the M13 
and phiX seen by Vy-PER. VirusSeq incorrectly reported non-integrated carp herpesvirus sequences 
(Table  5). VirusFinder with the recommended RINS database incorrectly reported human herpesvirus 
type 5 (HHV-5) which we analysed and found to be the harmless sequencing control library component 
M13. With the alternative gibVirus database, VirusFinder reported the non-integrated virus J02482M
Weighted 
candidates
Unambiguously 
aligned reads Virus ID
1655.3 1655 Enterobacteria phage phiX174 NC_001422.1
1.0 1 Pseudomonas phage Pf1 NC_001331.1
1.0 1 Caviid herpesvirus 2 NC_011587.1
1.0 1 Enterobacteria phage M13 NC_003287.2
1.0 1 Cercopithecine herpesvirus 2 NC_006560.1
Table 2.  Top viruses in a leukemia patient sample after final filtering, low stringency (threshold: 1 
chimera). Weighted candidates: For reads that align ambiguously to two or more viruses, we consider the 
top 3 viruses, assigning the highest weight to the first virus and the lowest weight (e.g. 0.3) to the last virus; 
the weight for an unambiguous alignment is 1.0.
Leukemia NA12878V L526401A 198T 268T
Data type WGS WGS RNA-Seq WGS WGS
HiSeq lanes 1.0 ≈ 0.0001 ≈ 0.33 ≈ 0.5 ≈ 0.5
Read length 2 × 101 bp 2 × mixed 2 × 50 bp 2 × 90 bp 2 × 90 bp
Read pairs 2.1 × 108 2 × 104 5.3 × 107 8.2 × 107 8.2 × 107
SURPI on EC2
fast – 14.8 h – – –
comprehensive – 24.5 h – – –
EC2 cost – $ 250.00 – – –
ViralFusionSeq 19.1 h 3 mins 4 h 12.3 h 12.4 h
VirusFinder
RINS virus db 14.5 h 2.7 h 9.8 h 21.5 h 15.4 h
gibVirus db 12.8 h 2.7 h 13.7 h 20.1 h 12.4 h
VirusSeq 195 h 17 mins 14.7 h 57.6 h 58.3 h
Vy-PER 1 h 7 mins 21 mins 19 mins 19 mins
Table 3.  Wall clock run time comparison between different bioinformatic pipelines for five examples. 
WGS whole genome sequencing, RNA-Seq whole transcriptome sequencing, EC2 Amazon elastic cloud 
computing. Wall clock times obtained on a 16 core computer, except for Vy-PER which only needed a single 
core of a 16 core computer and < 1 minute on the connected FPGA computer. The average number of WGS 
read pairs per HiSeq lane in our leukemia project was 1.65 × 108.
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10348M10379M10714M10749M10750M10866 (Table  5) and its de-novo assembled contig which our 
subsequent manual BLAST search identified as phiX174.
NA12878V synthetic genome data. The known human/virus chimeras were reported by Vy-PER 
but no other pipelines: Vy-PER reported 24 × human herpesvirus 3 (HHV-3), 1185 × phiX, and 2 × 
Example (viruses) ViralFusionSeq
VirusFinder 
(RINS)
VirusFinder 
(gibVirus) VirusSeq Vy-PER
Leukemia B2265L8 (phiX) TP – – – – phiX
FP – – – – –
NA12878V (HHV3, M13, 
phiX) TP – – – – HHV3, M13, phiX
FP – – – – CHV2 (singleton)
L52640A (HBV, phiX) TP HBV – – HBV HBV, phiX
FP – – – – –
198T (HBV) TP – – – – HBV
FP – – – – –
268T (HBV) TP HBV – – – HBV
FP – – – – –
Table 4.  human/virus chimera detection comparison between different bioinformatic pipelines for five 
examples. RINS VirusFinder-recommended database, gibVirus alternative database, TP true positive, FP 
false positive. phiX enterobacteria phage phiX174, HHV3 human herpesvirus 3, M13 enterobacteria phage 
M13, CHV2 caviid herpesvirus 2, HBV hepatitis B virus.
Example (viruses)
SURPI on 
EC2
Viral 
Fusion 
Seq
VirusFinder 
(RINS)
VirusFinder 
(gibVirus) VirusSeq Vy-PER
Leukemia (phiX, M13) TP not run – phiX J0 (phiX) – phiX
FP not run – HHV5 DE3, P7 carp herpesvirus –
NA12878V (HHV3, 
M13, phiX) TP HHV3, phiX – HHV3, phiX J0 (phiX), HHV3 – HHV3, M13, phiX
FP α 3, f1, G4, phiK – – S13 – CHV2 (singleton)
L52640A (HBV, phiX) TP not run HBV HBV, phiX HBV, phiX HBV HBV, phiX
FP not run – – – – –
198T (HBV) TP not run – HBV HBV – HBV
FP not run – – – carp herpesvirus –
268T (HBV) TP not run HBV HBV HBV – HBV
FP not run – – – carp herpesvirus –
Table 5.  Virus detection comparison between different bioinformatic pipelines for five examples, 
regardless of whether virus integration into the host genome was detected. EC2 Amazon elastic cloud 
computing, RINS VirusFinder-recommended database, gibVirus alternative database, TP true positive, FP 
false positive. phiX enterobacteria phage phiX174, M13 enterobacteria phage M13, J0 J02482M10348M
10379M10714M10749M10750M10866, HHV5 human herpesvirus 5, DE3 enterobacteria phage DE3, P7 
enterobacteria phage P7, HHV3 human herpesvirus 3, α 3 enterobacteria phage alpha3, f1 enterobacteria 
phage f1, G4 enterobacteria phage G4, phiK enterobacteria phage phiK, S13 bacteriophage S13, CHV2 caviid 
herpesvirus 2, HBV hepatitis B virus.
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M13 chimeras where the human reads were aligned with a mapping quality of at least 20. HHV-3 and 
phiX were reported as non-integrated viruses by SURPI and VirusFinder, but not by ViralFusionSeq 
or VirusSeq (Table  5). The known M13 phage was detected by no other pipeline. The herpes-like 
decoy sequences in this example data did not trigger any false positive calls by any pipeline except for 
Vy-PER, which reported a single caviid herpesvirus chimera. SURPI and VirusFinder (gibVirus data-
base) reported some false positive non-integrated enterobacteria phages. It should be noted that SURPI 
removes low-complexity reads as the first step, possibly over-aggressively, as true reads are removed 
which can be aligned by BWA (Supplementary Results online).
L526401A liver cancer sample (RNA). The known HBV integration loci were reported by Chen and 
colleagues26 and we reproduced these loci using their VirusSeq pipeline (Supplementary Table S1 online). 
All reported HBV loci were also detected by Vy-PER. Figure 3 displays the virus candidate loci in the 
genome that were detected by Vy-PER with the stringent default setting of at least ten supporting chime-
ras, i.e. at least ten virus/host paired-ends are required to support a virus integration locus, and Table 6 
lists the virus candidate loci in 1000 bp bins. Note that there are three integration loci on chromosome 16, 
one more than reported by VirusSeq. However, there is no split read to support this last locus, only the 
respective paired read that was aligned to hg19. In transcriptome data, a paired-end library may conceiv-
ably span two or more exons, which could lead to an additional candidate locus that is 4000 bp distant 
from the true integration locus. Table  7 shows the number of virus candidates reported by Vy-PER if 
singletons are enabled, and Fig. 4 shows the corresponding candidate loci. The VirusSeq pipeline includes 
gene annotation of the integration loci. However, the annotation is occasionally misleading, here for the 
integration locus chr4:63647816-63648816 which is 1.5 megabases distant from the 3’ end of the TECRL 
gene. This locus is nevertheless annotated as “TECRL/3-prime”, which the VirusSeq authors have also 
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Figure 3. Vy-PER ideogram summary plot. Positive example with true virus integrations: Publicly available 
whole transcriptome liver cancer data analysed with default sensitivity, showing HBV candidate loci on 
chromosomes 4, 11 and 16. The plot only shows integrations supported by 10 or more chimeras.
Chr Start End Candidates Virus
4 63647816 63648816 16.0 Hepatitis B virus
4 63651319 63652319 10.0 Hepatitis B Virus
11 12711328 12712328 71.0 Hepatitis B Virus
16 31413359 31414359 44.0 Hepatitis B Virus
16 31414755 31415755 18.0 Hepatitis B Virus
16 31418770 31419770 10.0 Hepatitis B Virus
Table 6.  Virus candidate loci in liver cancer sample after final filtering, high stringency (threshold: 10 
supporting paired-ends)
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copied into their publication26. The actual locus that VirusSeq computed is correct, but it is located in 
a gene desert. The nearest gene, LPHN3, is less than half the distance to TECRL. The ViralFusionSeq 
pipeline reported 10 clipped fusion sequences of which most are duplicates, but did not report their 
integration loci (Supplementary Table S2 online). Confusingly, the 100 bp fusion sequences reported by 
ViralFusionSeq are a tandem repeat of identical 50 bp reads. A BLAT search for the integration locus 
did not place any of these fusion reads correctly, due to their short length of only 50 nucleotides and the 
unavailable paired-end information. Only one such read aligned to the correct locus on chromosome 
11, but the alternative locus on chromosome 20 was ranked higher in the BLAT search. The VirusFinder 
pipeline did not report any virus integrations at all (Table 4 and Supplementary Table S1 online). Finally, 
no other pipeline reported the phiX chimeras seen by Vy-PER, but VirusFinder reported non-integrated 
phiX sequences.
198T liver cancer genome data. The liver cancer tissue sample harbours seven known human/HBV 
breakpoints23. We tested the sensitivity of all pipelines using a low-coverage subset of the whole genome 
data (Table 3). The only pipeline that was able to detect HBV in this data subset was Vy-PER. The virus 
integration event is detected by merely a single human/HBV chimera, but its locus is nevertheless vali-
dated by the known data23. There are no phiX chimeras in this data set, because the publicly deposited 
data has been “cleaned”. Looking at false positives, VirusSeq again incorrectly reported a non-integrated 
carp herpesvirus (Table 5).
268T liver cancer genome data. The liver cancer tissue sample harbours four known human/HBV 
breakpoints23. Only Vy-PER and ViralFusionSeq detected HBV integration in the low-coverage data 
subset of the full whole genome data. Vy-PER reported a single human/HBV chimera with a confidently 
mapped human read and a split human/virus read, which is validated by the known data23. ViralFusionSeq 
reported seven human/HBV fusion reads but did not resolve the coordinates (Supplementary Table 
S2 online). Manual BLAT and BLAST searches mapped four fusion reads to the same locus that was 
detected by Vy-PER, and the remaining three fusion reads to two further known loci (Supplementary 
Results online). We manually identified one HBV insertion to have microhomologies of four shared 
nucleotides between virus and host at the first end of the insertion (detected by Vy-PER), and of five 
shared nucleotides at the other end (detected by our manual searches for the fusion reads reported by 
ViralFusionSeq) (Supplementary Results online). The third insertion locus even showed a microhomology 
Weighted 
candidates
Unambiguously 
aligned reads Virus ID
181.0 181.0 Hepatitis B virus NC_003977.1
7.0 7.0 Enterobacteria phage phiX174 NC_001422.1
Table 7.  Top viruses in liver cancer (RNA-Seq) after final filtering, low stringency (threshold: 1 chimera).
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Figure 4. Vy-PER ideogram summary plot. HBV integration loci into the liver cancer genome detected at 
low stringency (threshold: 1 chimera), also showing detected phiX singletons.
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of 13 nucleotides. With respect to false positives, VirusSeq again incorrectly reported a non-integrated 
carp herpesvirus (Table 5).
Discussion
Virus integrations into the host genome of cancer tissue can be detected using paired-end whole genome 
or transcriptome sequencing data. However, the low number of expected true virus integrations may be 
difficult to distinguish from the noise of many false positive candidates if aiming to increase sensitivity. 
For example, some viruses target only a fraction of cell types, such as the human herpesvirus-6 (HHV-6) 
which has a tropism for CD4+ T-lymphocytes53. We therefore analysed false positive virus integration 
candidates and developed accurate filtering methods and efficient Python and R scripts that can be inte-
grated into any BWA-based next-generation sequencing analysis pipeline. The key strategies to eliminate 
false positives are to (a) remove reads consisting mainly of unspecific STRs or homopolymers, (b) remove 
virus candidates with sequences consisting mainly of unspecific STRs or homopolymers, (c) make sure 
that virus candidates do not align to the host genome, using highly accurate and sensitive alignment tools 
such as BLAT with its most sensitive setting or optionally Smith-Waterman, and (d) test for supporting 
candidates, as singletons may be artefacts. Finally, phiX and M13 are Illumina’s sequencing platform con-
trol spike-ins and not true virus infections. The optional FPGA-based Smith-Waterman alignments to the 
complete human genome are useful if FPGA hardware is available. Even without this optional stage, only 
quite a small number of false positives remain after using BLAT to align virus candidates to a reduced 
human genome sequence window of e.g. length 500 bps. In a clinical setting, it is not a practical option 
to use BLAT with its most sensitive settings to align candidates to the entire human genome, as this may 
take hours or days, but for pure research the run time is less important. In this context it is worth noting 
that BLAST uses DUST-based masking and does not align some human reads (Supplementary Results 
online), making BLAT or Smith-Waterman more suitable for this specific task.
The results shown here demonstrate that Vy-PER is sensitive, specific and efficient enough to be used 
as a first pipeline for routinely scanning all NGS data sets for virus integrations. The efficiency of Vy-PER 
is explained by its filtering design for speedy processing of genomic data that can be furthermore paral-
lelised for multi-lane genomes (map-reduce approach), and – when integrated into a BWA based pipeline 
– by avoiding the duplication of any expensive whole genome alignment computations. Once viruses of 
concern have been found in a sample, a more detailed analysis with ViralFusionSeq, VirusFinder and 
VirusSeq can then be performed. These latter pipelines are still in their early days and fairly complicated 
to install and understand, but each has its own merits. All of them also perform a search for viruses that 
did not integrate into the host genome. VirusSeq annotates the integration loci with gene information 
and computes breakpoints. VirusFinder is supposed to do the same, but our tested version (version 2) 
did not compute any integrations. ViralFusionSeq reports only the human/virus fusion reads but not 
the integration locus. Whereas Vy-PER was designed with concise clinical reporting in mind, the other 
pipelines are more detailed and do not provide a summary graphic or table. Vy-PER uses the NCBI virus 
genomes which are sufficient for uniquely pinpointing a virus at species level, and the summary tables 
show whether some or all virus reads were unambiguously assigned to a single virus species (Table 2). 
Similarly, for example, TIPP (Taxon Identification and Phylogenetic Profiling, http://www.cs.utexas.edu/
users/phylo/research/projects.html) dumbs down its level of detail as necessary, from strain to species or 
even to higher levels in the phylogeny, when ambiguous reads are encountered. However, the tested other 
pipelines currently still report viral strain information, which can give users a false sense of security, 
especially as there are vast homologies between the strains of a species, and we are unsure how correct 
these virus databases actually are. For example, the less experienced user may well be excited by the carp 
herpesvirus incorrectly reported in three out of five example data sets by one pipeline, or the human 
herpesvirus type 5 (instead of M13) incorrectly reported by another pipeline. No doubt each pipeline was 
developed for a specific type of virus and cancer data set, so it is probably worthwhile for a researcher to 
run a suspicious data set, i.e. one in which Vy-PER detected a virus, through each of these pipelines and 
to keep the potential problems in mind. It is for example remarkable that ViralFusionSeq detected viruses 
in only two of the five example data sets, but nevertheless detected three of the four fusion sequences in 
the low-coverage data subset of tumour sample 268T. Vy-PER only detected one of these fusions to be a 
virus integration event into the human host, because it searches only for chimeric paired-ends and not 
also for fusion sequences. Nevertheless, the scan for chimeras by Vy-PER was more sensitive than the 
approaches in other pipelines, correctly detecting the known chimeras in all five examples.
Surprisingly, Vy-PER is also able to detect non-integrated viruses. Taking the example of phiX (1% 
Illumina sequencing control library spike-in) and M13 (trace contamination of phiX library), the known 
presence of these non-integrated viruses is detected as chimeric virus/human read-pair artefacts. In our 
whole genome leukemia sequencing study, on average 160 phiX/human chimeras were detected per 
HiSeq lane (0.0001% of read-pairs). The chimeric sequencing artefacts can be interpreted as randomly 
sampled non-integrated virus sequences. Indeed, on the related topic of bacterial identification from 
shotgun sequencing, it was recently suggested54 that only 100 randomly sampled 100 bp Illumina reads 
from pure bacterial DNA could be sufficient to identify the bacterial strain with over 90% specificity. 
For detecting non-integrated pathogens, the sensitivity is better if all paired-end reads that could not be 
aligned to the human genome are scanned. The scan can be followed by our approach to eliminate false 
positives, which is not limited to chimeras or to viruses.
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As a matter of speculation, future studies may find that the concept of a human-virus breakpoint at a 
single base pair is not appropriate for all viruses. On the one hand it is known that retroviruses integrate 
at a distinct breakpoint when an integrase binds to its preferred nucleotide motifs55 which are then dupli-
cated and flank the integrated viral sequence56. However, other viruses, specifically HBV, may integrate 
using the non homologous end joining (NHEJ) pathway57,58 which implies a shared microhomology 
between virus and host at the integration site, as observed in our manual inspections of the integration 
sites in data set 268T. The NHEJ mechanism suggests that the HBV integration into the human genome 
may not be the driver event for genomic instability, but that the HBV integration may have occurred as 
a passenger event after double-stranded breakage of the human chromosome.
In the treatment of HIV infections, cART may be unable to completely eliminate HIV if replication 
competent proviruses are integrated into long lived or proliferating CD4+ cells. Of particular interest 
are the integration loci which are preferentially located in genes that promote cell proliferation6,7. Using 
Vy-PER, the integration loci in clonally expanded cell populations would be detectable either using 
normal paired-end shotgun sequencing or even better, using targeted sequencing like linker-mediated 
polymerase chain reaction6 or integration site loop amplification7. To speed up the bioinformatic analy-
sis, the full virus genome reference could be replaced by just the HIV genome references.
Finally, the wealth of incidental metagenomic findings in human NGS data is highly exciting for 
potential pathogen detection, even when only microscopically low read numbers are available that our 
approach can detect and assign to a virus genome.
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